Europe’s Biotech Standout Faces Crucial Year After 1,300% Rally

French biotech company Abivax SA started the year with a market value of less than $500 million. After a meteoric rally, it’s now worth more than $8 billion — and...

By Lisa Pham, Sonja Wind · Bloomberg Markets

French biotech company Abivax SA started the year with a market value of less than $500 million. After a meteoric rally, it’s now worth more than $8 billion — and some analysts see the potential for even more gains.